NCT01705080终止不适用
IntErnational Non-randomized, Single-arm, Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 276
- 试验地点
- 33
- 主要终点
- Mean Reduction in Office Systolic Blood Pressure From Baseline to 6 Months
研究概览
简要总结
The purpose of this post market clinical investigation is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled hypertension.
详细描述
This is a post market, prospective, multicenter, non-randomized, single arm study of the EnligHTN™ Renal Denervation System. Approximately 500 subjects with uncontrolled hypertension will undergo renal artery ablation at approximately 40 investigational sites located internationally and will be followed up to five years post procedure.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥ 18 years of age at time of consent
- •Subject must be able and willing to provide written informed consent
- •Subject must be able and willing to comply with the required follow-up schedule
- •Subject has office Systolic Blood Pressure ≥ 140 mmHg at confirmatory visit
- •Subject has a daytime mean Systolic Ambulatory Blood Pressure > 135 mmHg within 90 days prior to procedure
- •Subject has established hypertension (diagnosed ≥12 month prior to baseline) and is on a guideline based drug regimen at a stable and fully tolerated dose consisting of ≥ 3 anti-hypertensive medications (including 1 diuretic) or subject has a documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
排除标准
- •Subject has significant renovascular abnormalities such as renal artery stenosis > 30%
- •Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts
- •Subject has hemodynamically significant valvular heart disease as determined by study investigator
- •Subject has a life expectancy less than 12 months, as determined by the Investigator
- •Subject is participating in another clinical study which has the potential to impact their hypertension management (pharmaceutical/device/homeopathic)
- •Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods
- •Subject has active systemic infection
- •Subject has renal arteries with diameter(s) < 4 mm in diameter
- •Subject has an estimated GFR <15 mL/min per 1.73 m^2 using the MDRD formula
- •Subject had a renal transplant or is awaiting a renal transplant
- •Subject has blood clotting abnormalities
结局指标
主要结局
Mean Reduction in Office Systolic Blood Pressure From Baseline to 6 Months
时间窗: Baseline to 6 months
Office blood pressure corresponds to the blood pressure measured by the doctor or the nurse/staff in the office or in the clinic during the participant visit. Office Blood Pressure measurements was recorded as the average Blood Pressure of three measurements. If there was a change in medication after the office Blood Pressure assessment was completed an additional set of office Blood Pressure measurements was performed.
次要结局
- Acute Safety: Percentage of Participants With Peri-procedural Events Within 30 Days Post-procedure(30 days post procedure)
- Midterm Safety: Percentage of Participants With New Renal Artery Stenosis and/or Aneurysm at Ablation Site at 6 Months(6 months)
- Midterm Safety: Mean Change in eGFR (mL/Min/1.73m²) From Confirmatory Visit to 6 Months(Confirmatory visit to 6 months)
- Long Term Safety: Percentage of Participants With New Renal Artery Stenosis and/or Aneurysm at Ablation Site at 2 Years(2 years)
- Long Term Safety: Percentage of Participants With New Renal Artery Stenosis and/or Aneurysm at Ablation Site at 5 Years(5 years)
- Long Term Safety: Mean Change in eGFR (mL/Min/1.73m²) From Confirmatory Visit to 2 Years(Confirmatory visit to 2 years)
- Long Term Safety: Mean Change in eGFR (mL/Min/1.73m²) From Confirmatory Visit to 5 Years(Confirmatory visit to 5 years)
- Mean Change in Ambulatory Systolic Blood Pressure From Baseline to 6 Months(Baseline to 6 months)
- Mean Change in Ambulatory Diastolic Blood Pressure From Baseline to 6 Months(Baseline to 6 months)
- Mean Change in Office Diastolic Blood Pressure From Baseline to 6 Months(Baseline to 6 months)
- Percentage of Participants Achieved Office Systolic Blood Pressure < 140 mmHg at 6 Months(6 months)
- Mean Change in Office Systolic Blood Pressure From Baseline to 1 Year Post Denervation(Baseline to 1 year)
- Mean Change in Office Systolic Blood Pressure From Baseline to 2 Years Post Denervation(Baseline to 2 years)
- Mean Change in Office Systolic Blood Pressure From Baseline to 3 Years Post Denervation(Baseline to 3 years)
- Mean Change in Office Systolic Blood Pressure From Baseline to 4 Years Post Denervation(Baseline to 4 years)
- Mean Change in Office Systolic Blood Pressure From Baseline to 5 Years Post Denervation(Baseline to 5 years)
- Mean Change in Office Diastolic Blood Pressure From Baseline to 1 Year Post Denervation(Baseline to 1 year)
- Mean Change in Office Diastolic Blood Pressure From Baseline to 2 Years Post Denervation(Baseline to 2 years)
- Mean Change in Office Diastolic Blood Pressure From Baseline to 3 Years Post Denervation(Baseline to 3 years)
- Mean Change in Office Diastolic Blood Pressure From Baseline to 4 Years Post Denervation(Baseline to 4 years)
- Mean Change in Office Diastolic Blood Pressure From Baseline to 5 Years Post Denervation(Baseline to 5 years)
- Mean Change in Ambulatory Systolic Blood Pressure From Baseline to 1 Year Post Denervation(Baseline to 1 year)
- Mean Change in Ambulatory Systolic Blood Pressure From Baseline to 2 Years Post Denervation(Baseline to 2 years)
- Mean Change in Ambulatory Systolic Blood Pressure From Baseline to 3 Years Post Denervation(Baseline to 3 years)
- Mean Change in Ambulatory Systolic Blood Pressure From Baseline to 4 Years Post Denervation(Baseline to 4 years)
- Mean Change in Ambulatory Systolic Blood Pressure From Baseline to 5 Years Post Denervation(Baseline to 5 years)
- Mean Change in Ambulatory Diastolic Blood Pressure From Baseline to 1 Year Post Denervation(Baseline to 1 year)
- Mean Change in Ambulatory Diastolic Blood Pressure From Baseline to 2 Years Post Denervation(Baseline to 2 years)
- Mean Change in Ambulatory Diastolic Blood Pressure From Baseline to 3 Years Post Denervation(Baseline to 3 years)
- Mean Change in Ambulatory Diastolic Blood Pressure From Baseline to 4 Years Post Denervation(Baseline to 4 years)
- Mean Change in Ambulatory Diastolic Blood Pressure From Baseline to 5 Years Post Denervation(Baseline to 5 years)
研究者
研究点 (33)
Loading locations...
相似试验
已完成
不适用
Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence ProductsUrinary IncontinenceNCT04846270Essity Hygiene and Health AB35
已完成
不适用
A Clinical Investigation With Epaderm® CreamEczemaPsoriasisDry Skin EczemaNCT03738163Molnlycke Health Care AB121
招募中
不适用
ACOART BTK RENEW：A Post Market Clinical StudyPeripheral Artery DiseaseNCT04885985Acotec Scientific Co., Ltd107
招募中
不适用
Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal ObstructionAcute RhinitisNasal ObstructionRhinosinusitisRhinopharyngitisAllergic RhinitisNCT06580210Laboratoires Gilbert114
招募中
不适用
ACOART AVF RENEW: A Post Market Clinical StudyStenosis of Native Hemodialysis Arteriovenous FistulasNCT06205576Acotec Scientific Co., Ltd164